• Moritz Fritzenwanker, Can Imirzalioglu, Susanne Herold, Florian M Wagenlehner, Klaus-Peter Zimmer, and Trinad Chakraborty.
• German Center for Infection Research (DZIF); Institute for Medical Microbiology, University of Gießen; Department of Urology, Pediatric Urology, and Andrology, University of Gießen; Clinical Infectiology, Department of Medicine II, University of Gießen; German Center for Lung Research (DZL); Department of General Pediatrics and Neonatology, Center for Pediatric and Adolescent Medicine, University of Gießen.
• Dtsch Arztebl Int. 2018 May 21; 115 (20-21): 345352345-352.

BackgroundRates of colonization and infection with carbapenem-resistant Gram-negative pathogens are on the rise, particularly in southeastern European countries, and this is increasingly true in Germany as well. The organisms in question include enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli and non-fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. As the carbapenems have been the gold standard to date for the systemic treatment of serious infections with Gram-negative bacteria, carbapenem resistance presents new and difficult challenges in therapeutic decision-making, particularly because of the high frequency of coresistance.MethodsThis review is based on pertinent publications retrieved by a selective search in PubMed and on other applicable literature.ResultsMultiresistant Gram-negative (MRGN) pathogens are classified in Germany according to their resistance to four different classes of antibiotics; fluoroquinolones, piperacillin, third-generation cephalosporins, and carbapenems. Quadruple MRGN pathogens are resistant to all four groups, triple MRGN pathogens to three of them. There are a number of therapeutic alternatives to carbapenems that can be applied with the aid of sensitive microbiological and/or molecular genetic testing. The following antibiotics are often the only ones that can be used to treat quadruple MRGN pathogens: colistin, aminoglycosides, tigecycline, fosfomycin, ceftazidime/avibactam, and ceftolozan/tazobactam. Carbapenems, too, may still be an option in certain situations. There is also evidence that combinations of antibiotics against which the pathogen is resistant individually can some- times be a valid treatment option; these include combinations of colistin with one or two carbapenems.ConclusionThe treatment of severe infection with carbapenem-resistant pathogens should be individualized and carried out in an interdisciplinary framework, in consideration of antibiotic pharmacokinetics and pharmacodynamics in each case. The treat- ment options are based on evidence from in vitro studies, retrospective studies, and case series, which must be interpreted with caution. Randomized clinical trials are needed to test each of the various combined approaches.

50 keywords...

hide…